Ajanta Pharma - Public Comps and Valuation Multiples

Ajanta Pharma Overview

About Ajanta Pharma

Ajanta Pharma Ltd is a drug manufacturing company with a focus on specialty pharmaceutical products. The company maintains a presence while generating the vast majority of its revenue in India. The company aims to successfully select molecules and products for development while enhancing its research and development capabilities. The company works to develop formulations in different dosages such as tablets, creams, injectables, capsules, liquids, and lotion. The company's manufacturing plants are located in India.

Founded

1979

HQ

Employees

9.6K+

Website

ajantapharma.com

Sectors

Drug Development & Therapeutics
BioTech

Financials

LTM Revenue $557M

LTM EBITDA $153M

EV

$3.3B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Ajanta Pharma Financials

As of September 2025, Ajanta Pharma reported last 12-month revenue of $557M and EBITDA of $153M.

In the same period, Ajanta Pharma generated $415M in LTM gross profit and $111M in net income.

See Ajanta Pharma valuation multiples based on analyst estimates

Ajanta Pharma P&L

In the most recent fiscal year, Ajanta Pharma reported revenue of $517M and EBITDA of $153M.

Ajanta Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Ajanta Pharma valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$557M	XXX	$517M	XXX	XXX	XXX
Gross Profit	$415M	XXX	$390M	XXX	XXX	XXX
Gross Margin	75%	XXX	75%	XXX	XXX	XXX
EBITDA	$153M	XXX	$153M	XXX	XXX	XXX
EBITDA Margin	28%	XXX	30%	XXX	XXX	XXX
EBIT	$137M	XXX	$127M	XXX	XXX	XXX
EBIT Margin	25%	XXX	25%	XXX	XXX	XXX
Net Profit	$111M	XXX	$104M	XXX	XXX	XXX
Net Margin	20%	XXX	20%	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Ajanta Pharma including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $557M. EBITDA for the last twelve months was $153M. In the most recent fiscal year, Ajanta Pharma achieved $517M in revenue and $153M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$557M	Analyst estimates available to subscribers	$517M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$415M	Analyst estimates available to subscribers	$390M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	74.6% gross margin	Analyst estimates available to subscribers	75.4% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$153M	Analyst estimates available to subscribers	$153M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	27.5% EBITDA margin	Analyst estimates available to subscribers	29.5% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$137M	Analyst estimates available to subscribers	$127M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	24.6% EBIT margin	Analyst estimates available to subscribers	24.6% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$111M	Analyst estimates available to subscribers	$104M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	19.9% net profit margin	Analyst estimates available to subscribers	20.1% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Ajanta Pharma

This financial data table provides comprehensive performance metrics for Ajanta Pharma, a company based in India. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Ajanta Pharma generated $557M in revenue over the last twelve months.
The company achieved $153M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $415M.
Net income over the last twelve months reached $111M.

Fiscal Year Performance

In the most recent fiscal year, Ajanta Pharma reported $517M in total revenue.
Fiscal year EBITDA was $153M.
The company maintained a gross profit margin of 75.4% in the most recent fiscal year.
EBITDA margin for the fiscal year was 29.5%.
Net profit margin reached 20.1% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Ajanta Pharma. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Ajanta Pharma Stock Performance

Ajanta Pharma has current market cap of INR 300B (or $3.4B), and EV of INR 294B (or $3.3B).

Market Cap Evolution

Ajanta Pharma Stock Data

As of October 3, 2025, Ajanta Pharma's stock price is INR 2399 (or $27).

See Ajanta Pharma trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$3.3B	$3.4B	XXX	XXX	XXX	XXX	$0.89

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Ajanta Pharma Valuation Multiples

Ajanta Pharma's trades at 6.6x EV/Revenue multiple, and 22.1x EV/EBITDA.

See valuation multiples for Ajanta Pharma and 15K+ public comps

Ajanta Pharma Financial Valuation Multiples

As of October 3, 2025, Ajanta Pharma has market cap of $3.4B and EV of $3.3B.

Equity research analysts estimate Ajanta Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Ajanta Pharma has a P/E ratio of 30.5x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$3.4B	XXX	$3.4B	XXX	XXX	XXX
EV (current)	$3.3B	XXX	$3.3B	XXX	XXX	XXX
EV/Revenue	5.9x	XXX	6.6x	XXX	XXX	XXX
EV/EBITDA	21.6x	XXX	22.1x	XXX	XXX	XXX
EV/EBIT	24.2x	XXX	26.5x	XXX	XXX	XXX
EV/Gross Profit	8.0x	XXX	n/a	XXX	XXX	XXX
P/E	30.5x	XXX	33.5x	XXX	XXX	XXX
EV/FCF	43.9x	XXX	37.3x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Ajanta Pharma Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Ajanta Pharma Margins & Growth Rates

Ajanta Pharma's last 12 month revenue growth is 12%

Ajanta Pharma's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $27K for the same period.

Ajanta Pharma's rule of 40 is 42% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Ajanta Pharma's rule of X is 58% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Ajanta Pharma and other 15K+ public comps

Ajanta Pharma Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	12%	XXX	13%	XXX	XXX	XXX
EBITDA Margin	28%	XXX	30%	XXX	XXX	XXX
EBITDA Growth	16%	XXX	11%	XXX	XXX	XXX
Rule of 40	42%	XXX	42%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	58%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.1M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$27K	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	7%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	51%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial